BioNTech Launches Exchange Offer for CureVac Shares

TL;DR

BioNTech is buying CureVac shares, starting Oct 22, 2025.

AI Summary

On October 22, 2025, BioNTech SE announced the commencement of an exchange offer for all outstanding shares of CureVac N.V. This filing is a Form 6-K report submitted to the SEC.

Why It Matters

This move could signal a significant consolidation or strategic shift within the mRNA vaccine and therapeutics sector, potentially impacting competition and innovation.

Risk Assessment

Risk Level: medium — The success of the exchange offer and its impact on BioNTech's market position and financial health are subject to various factors and potential regulatory hurdles.

Key Players & Entities

• BioNTech SE (company) — Registrant and offeror
• CureVac N.V. (company) — Target of exchange offer
• October 22, 2025 (date) — Date of press release and commencement of exchange offer

FAQ

From the Filing

0001193125-25-246740.txt : 20251022 0001193125-25-246740.hdr.sgml : 20251022 20251022160109 ACCESSION NUMBER: 0001193125-25-246740 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20251022 FILED AS OF DATE: 20251022 DATE AS OF CHANGE: 20251022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251410095 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 d42810d6k.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On October 22, 2025, BioNTech SE (the “Company”) issued a press release announcing the commencement of its exchange offer for all outstanding shares of CureVac N.V. A copy of the press release is attached hereto as Exhibit 99.1. This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company’s registration statement on Form F-4 (File No. 333-289468) and registration statements on Form S-8 (File Nos. 333-277105, 333-269740 and 333-253263) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Prof. Dr. Ugur Sahin By: /s/ Dr. Sierk Poetting Name: Prof. Dr. Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: October 22, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. EX-99.1 2 d42810dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. • Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its oncology strategy • CureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be available at www.envisionreports.com/CureVacOffer for the duration of the exchange offer • Information on how CureVac shareholders can participate in the exchange offer is available via Georgeson LLC, the information agent for the exchange offer, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect), or Curevacoffer@georgeson.com • Exchange offer will expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in accordance with the term